Skip to main content
  • Home
  • Library
  • Read
    • Popular
    • Charts
    • Browse
    • Categories
    • Wikis
    • Glossary
  • Request
  • Activity
  • Leaderboard
  • Help
Our Apps
  • DaoSearch
  • Narratorr
Social
  • Discord
  • Patreon
I Can Extract Side Effects
Chapter 521

Experimental Protocol Design

2,489 words 8 min read 6 views 3mo ago Source ​
Skip to the end of the chapter
Prev
Next

No drug has ever put Wei Kang in such a difficult position.

"The results of the Phase I trials were excellent. After taking the drug, the levels of Antioxidant Enzyme in the human body were greatly increased."

"But developing new drugs requires a specific disease to be identified, so that the right treatment can be given, useful data can be obtained, and the drug can be approved for market launch."

"Low levels of Antioxidant Enzyme in the human body may make people more susceptible to illness, but it is not a specific disease in itself. I need to choose an indication before I can continue with subsequent clinical trials."

"Otherwise, we can only reduce the dosage and turn it into a health supplement."

After much deliberation, Wei Kang remained hesitant, unsure which disease to choose to design the Phase III clinical trial protocol in order to achieve clinical success.

Based on past cases, clinical trials of antioxidants often fail to yield statistically significant results.

Although some antioxidants have achieved good results in Volkswagen health and disease prevention, very few are used in clinical practice as therapeutic drugs.

For an antioxidant to be used clinically, it should meet the following requirements:

First, the drug needs to be delivered to the designated area in the body.

Secondly, evaluation indicators need to be set appropriately in clinical trials in order to make statistical comparisons.

Finally, new methods need to be developed to elucidate the mechanism of action of antioxidants.

Drug delivery and evaluation metrics are not the main challenges; the real difficulty lies in elucidating the therapeutic mechanism of antioxidant effects on a particular disease and proving it with clinical data.

Therefore, he had to think carefully, select suitable symptoms, and design clinical trial protocols.

In a sense, this new drug is an endogenous antioxidant.

Animal Experiment have shown that after injection, the levels of Antioxidant Enzyme in mice and pigs increased significantly in a short period of time, demonstrating a good therapeutic effect on some oxidative damage.

In one of the animal models, researchers even used X-ray to cause radiation damage to the experimental group of animals. Because it was ionizing radiation, it generated a large number of Free Radicals damages in the animals' bodies, causing persistent pathological changes.

This is because Free Radicals have unpaired electrons, which can steal electrons from healthy cells.

When proteins in healthy cells lose electrons, the chemical bonds of these molecules break, which can easily lead to a series of abnormalities, creating a vicious cycle that causes continuous damage to the cells.

However, after the injection of the Antioxidant Enzyme -promoting drug, the Antioxidant Enzyme were rapidly synthesized in the body, and the radiation-induced oxidative damage was well restored, which was in stark contrast to the control group that did not take any drugs.

Not only were the Animal Experiment highly effective, but in Phase I trials, healthy individuals who took a certain dose showed no side effects and a significant increase in SOD levels in their bodies.

Even some patients with low SOD levels in their bodies saw their SOD levels return to normal after taking the new drug for treatment.

Such experimental data is sufficient to confirm the safety and effectiveness of the drug.

SOD, short for Superoxide Dismutase, is widely present in the human body. It can scavenge superoxide anion Free Radicals and inhibit the oxidative effect of Free Radicals.

Because Free Radicals have extremely short biological half-lives, are very unstable, difficult to measure directly, and are generated very universally, and because the human body has a strong antioxidant capacity, SOD detection is the most effective means of reflecting Free Radicals levels.

Clinically, it is one of the important indicators reflecting the state of Free Radicals metabolism in the human body. Therefore, observing the level of SOD can indirectly reflect the body's ability to eliminate Free Radicals and the health status of the human body.

The normal range for serum SOD in humans is around 110-215 u/mL.

If the levels decrease significantly, it indicates that Free Radicals are beginning to harm human health, and in severe cases, they can lead to a series of brain and heart diseases, requiring timely intervention.

If the levels are higher than the normal range, it also indicates the occurrence of an acute illness, leading to immune stress and an inflammatory response in the body.

In a healthy human body, the formation and elimination of Free Radicals are in a dynamic balance; neither too high nor too low levels are good.

Currently, there is great interest in the Clinical Application of Antioxidant Enzyme (SOD), and recombinant Cu-SOD, Zn-SOD, and Mn-SOD have been synthesized, but their plasma half-lives are all very short.

To improve this deficiency, scientists have designed a large number of structurally modified SODs, such as PEGylated SOD, Ficollated SOD, Hyaluronylated SOD, and Albumin-conjugated SOD, to prolong the plasma half-life of SOD.

They have been used to treat Ischemia-Reperfusion Injury or inflammatory response, but these drugs have not shown significant differences in in vivo trials, and there are no literature reports on human double-blind clinical trials on the effectiveness of SOD in chronic inflammation or autoimmune diseases. Only recombinant Cu-SOD and Zn-SOD injections are effective in preterm infants.

Therefore, it is quite difficult to find a disease that is directly related to antioxidation and can be cured by medicine.

Everyone knows that Free Radicals can cause many diseases, such as Cancer, aging, heart disease, Diabetes, and so on.

Various studies also provide ample data to support this conclusion.

But can taking medication to increase SOD levels and eliminate excess Free Radicals in the body immediately cure these diseases?

No one has conclusive clinical evidence.

Proving efficacy in the laboratory is far from enough; large-scale clinical trials must be conducted to obtain statistically significant differences before a drug can be successfully marketed.

Therefore, Wei Kang must carefully select experimental targets. Chronic diseases such as Diabetes, Coronary Heart Disease, and Hypertension, although they are good conditions, have complex causes, too many interfering factors, and long clinical cycles, often requiring several years of follow-up, making them not the best choice.

The ideal approach is to select a disease with obvious drug efficacy and rapid results as the experimental target to obtain the most important evaluation indicators.

After the product is launched on the market, treatment for other indications will be carried out with the support of doctors.

This involves buying a short-distance ticket first, boarding the train, and then purchasing a long-distance ticket.

This is a legitimate and aboveboard approach by pharmaceutical companies within the rules, and it is perfectly compliant, so no one can find fault with it.

After all, there are many such examples in the history of drug discovery.

For example, at the beginning of the last century, scientists were researching antimalarial drugs, but they discovered that a certain drug had an unexpected sedative effect. They then gave it directly to patients and were surprised to find that the effect was surprisingly good. The patients stopped crying and making a fuss after taking it.

Next, Promethazine, a psychiatric "Penicillin," was developed, saving countless mental patients from the tragic fate of Prefrontal Lobotomy.

According to Wei Kang's thinking, if they directly choose the most difficult option, such as treating Coronary Heart Disease, it would take three to five years to obtain enough clinical data to bring it to market.

Then, compared with other lipid-lowering drugs that have immediate effects, the effect is very slow and the treatment time is very long, making it not competitive at all.

There is such a tragic case in history.

In the 1970s, Probucol was the only FDA-approved Antioxidant Drug on the market, mainly used to treat Coronary Heart Disease caused by Atherosclerosis. It is an antioxidant lipid-lowering drug.

However, due to the rise of Statins lipid-lowering mechanism is clearer, their efficacy is more defined, and their treatment effect is better.

This shifted the focus of the medical community in combating Arteriosclerosis to these drugs, causing Probucol to quickly lose its market share and sales to plummet. After its patent expired, due to low profits, it voluntarily withdrew from the market with the FDA.

This is a tragic case of a drug that failed to find its niche and discover its strengths. As Antioxidant Drug, it was chosen to treat Coronary Heart Disease, but it lost out to lipid-lowering drugs and ended up being withdrawn from the market.

Wei Kang doesn't want such a tragedy to happen to its own drugs.

Even the strongest oxidant, touted as being available for clinical use, has suffered a major setback in the treatment of heart disease. Naturally, he wouldn't be stubborn and choose to tackle the most difficult chronic diseases head-on.

He decided to take an unconventional approach, starting with the simplest steps and getting the company listed first.

To achieve this result, the ideal experimental target should have the most important indicators—mortality and the incidence of specific diseases.

In other words, the mortality rate is relatively high if medication is not used.

However, the use of medication can greatly reduce the mortality rate.

With this comparison, even a passerby, let alone someone from the Drug Administration Bureau, can tell which drug is better.

The incidence rate of specific diseases is easier to understand.

This mainly refers to the probability of developing a specific disease under different levels of Free Radicals in the body.

Only by meeting these two indicators can the experimental data be evaluated and convincing data be obtained.

"I've made up my mind, I'll choose this illness."

Wei Kang finally made up his mind and made his choice.

"Acute Radiation Sickness is a disease for which there is no very effective treatment yet, and the mortality rate is very high."

"The cause of this disease is very clear: it is caused by the human body being exposed to a large amount of radiation in a short period of time. The main mechanism of radiation damage is Free Radicals damage. As long as this problem is solved, the patient will naturally recover."

"Various studies indicate that the radiolysis of molecules is the main cause of Free Radicals. Free Radicals not only play an important role in the damage process of Acute Radiation Sickness, but also continue to cause tissue damage during the recovery period of Radiation Sickness."

"The chain reaction of Reactive Oxygen Species can lead to oxidative damage to biomolecules, triggering early radiation effects and post-radiation effects such as fibrosis."

"Therefore, blocking the production of Reactive Oxygen Species and clearing away existing Reactive Oxygen Species is an effective strategy for preventing radiation damage."

"SOD, which uses oxygen as a substrate, is an important enzyme for organisms to defend against oxidative damage and is also a relatively ideal protectant against radiation damage."

"After SOD was discovered in the 1970s, it was found that it could protect biochemical systems from the poisoning of superoxide anion Free Radicals and reduce radiation damage in a wide range of biochemical systems."

"My new drug can enhance the SOD (Antioxidant Enzyme) in the human body in a short period of time, which can protect human tissues from radiation damage. It can be said to be very effective."

"However, not many people get this disease, and it's not easy to gather enough people to participate in Phase III, so we need to find another alternative disease."

Wei Kang's gaze slowly moved across the screen as he made his selection. "I don't have many choices left."

"Let's go with this one, ischemia-reperfusion injury."

"There are three main types of conditions: restoration of blood supply after systemic circulatory disorder, restoration of blood flow after ischemia in a certain tissue or organ, or reperfusion injury caused by the reopening of a certain blood vessel. In any of these cases, excessive oxidative damage to the tissue will occur."

"For example, cardiopulmonary resuscitation after cardiac arrest can cause Myocardial Ischemia -reperfusion injury. Other procedures such as arterial bypass surgery, organ transplantation, and limb replantation can also cause tissue damage and lead to fatal diseases."

"In fact, the main factor that causes tissue damage is not ischemia itself, but the damage caused by excessive Free Radicals attacking the tissue cells that have regained blood supply after the blood supply is restored."

"The main reason is that the synthesis of SOD, Antioxidant Enzyme that scavenge Free Radicals, is impaired in ischemic tissue. As long as the synthesis of SOD can be enhanced, it will have a protective effect against such damage."

"This is also a very suitable disease for clinical application of this drug."

Wei Kang's thoughts continued to wander. Free Radicals cause a wide variety of diseases, almost anything imaginable.

Although not many met his requirements, it was still quite an eye-opener for him.

"Besides these two diseases, Antioxidant Enzyme are also important in the body's detoxification process."

"Not only can radiation generate Free Radicals, but many chemical drugs such as antibiotics, pesticides, anesthetics, and aromatic hydrocarbons can also induce the generation of Free Radicals. Antioxidant Enzyme break down these toxins in the human liver and kidneys."

"Perhaps this new drug also has the potential to become an antidote, and can treat some of the toxic effects of chemicals on the human body."

"In short, this new drug has immense potential, and there are many areas waiting for me to explore."

Having solved the clinical protocol design problem, Wei Kang felt much better.

He quickly gave the order to officially begin the Phase III Clinical Trial of the Antioxidant Enzyme Accelerator.

At the same time, the excellent effects of this drug gave him a new idea.

That is, after the new drug is officially launched, the number of people taking the drug will increase, and its safety and effectiveness will be proven on a larger population sample.

He would then modify the drug, reducing its efficacy and dosage while significantly improving its safety, transforming it into a long-term preventative anti-aging drug.

As a youth version, further basic clinical research will be conducted.

At that time, instead of having patients participate in clinical trials, a large number of middle-aged and elderly people will be recruited, and the indications for verification will become anti-aging.

For ordinary people, the aging process becomes unstoppable after the age of 30.

As we age, the synthesis of Antioxidant Enzyme in our bodies gradually declines, and the level of Free Radicals increases day by day. Eating foods rich in SOD from external sources has very limited effect, and we cannot replenish our own energy production. Who wouldn't be anxious about this?

There is a preventative anti-aging drug that can promote the synthesis of SOD, enhance the body's ability to scavenge Free Radicals, and keep the body at a healthy level, thus naturally delaying the aging process.

The reason we are not conducting clinical research in this area now is that such preventative clinical trials fall under the category of basic research.

It often takes 5 to 10 years to reach a definitive conclusion, and this is not necessarily a positive result. It is very likely that after 5 years, a negative conclusion will be reached.

During this period, researchers conducted long-term follow-ups with volunteers, with tens of thousands of participants.

Three Purities is not incapable of conducting such time-consuming and costly basic clinical studies on anti-aging, but it should only be done after the drug has proven its effectiveness and been officially launched on the market; otherwise, it would be a waste of time and effort.

Thinking of this, Wei Kang clenched his fists, a surge of heroic spirit welling up within him.

"I'm here for basic clinical research on anti-aging drugs."

"Let's entrust human health to the Three Purities."

End of Chapter
Prev
NovelSummaries
Next

Explore the wiki

Wei Kang
Three Purities

Comments

No comments yet.
AboutStatsAPIChangelogStatusContactPrivacyTermsDMCA
© 2026 RandomTranslator·v3.26·RSS